.webp?width=217&height=60&name=Screenpoint-Med%20(1).webp "Screen Point Medical")
MASAI RCT: 12% reduction in interval cancer rate using Transpara
%20(1).png)
MASAI RCT: 12% reduction in interval cancer rate using Transpara
Transpara® Breast AI Selected for $16M PRISM Randomized Controlled Trial in USA
.png)
Transpara® Breast AI Selected for $16M PRISM Randomized Controlled Trial in USA
ScreenPoint Medical Enables Transpara® Breast AI within Precision Imaging Network, part of Microsoft for Healthcare
.png)
ScreenPoint Medical Enables Transpara® Breast AI within Precision Imaging Network, part of Microsoft for Healthcare
MASAI RCT: 12% reduction in interval cancer rate using Transpara
MASAI RCT: 12% reduction in interval cancer rate using Transpara
New research highlights Transpara Detection ‘s impact on the MASAI randomized controlled trial’s final endpoint: interval cancers.
January 30, 2026
Study from UCLA shows Transpara could help identify hidden breast cancer
.png)
Study from UCLA shows Transpara could help identify hidden breast cancer
New research suggests Transpara Detection can be used to spot cancers radiologist may miss
April 30, 2025
Transpara Improves Cancer Detection by Decreasing False Negative Cancers
.png)
Transpara Improves Cancer Detection by Decreasing False Negative Cancers
Transpara Accurately Identified Half of False Negative Cancers – all Invasive, and Often in Dense Breasts – in a Large Retrospective Study
November 19, 2024